DaVita Inc. (NYSE:DVA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have earned an average recommendation of “Hold” from the five analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $161.80.

Several equities analysts have recently weighed in on the company. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th.

DaVita Stock Up 2.2 %

Shares of DaVita stock opened at $169.97 on Wednesday. DaVita has a 52-week low of $103.40 and a 52-week high of $170.29. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The business’s 50 day simple moving average is $157.59 and its 200 day simple moving average is $153.35. The firm has a market cap of $13.94 billion, a PE ratio of 18.34, a P/E/G ratio of 0.81 and a beta of 0.92.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.85 EPS. On average, analysts predict that DaVita will post 9.71 earnings per share for the current fiscal year.

Institutional Trading of DaVita

A number of hedge funds have recently made changes to their positions in the business. Transcendent Capital Group LLC acquired a new stake in DaVita during the 3rd quarter valued at $25,000. Blue Trust Inc. lifted its stake in shares of DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after buying an additional 119 shares during the last quarter. Quarry LP bought a new stake in shares of DaVita during the 3rd quarter worth about $60,000. Versant Capital Management Inc grew its stake in DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in DaVita in the 2nd quarter valued at about $68,000. 90.12% of the stock is owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.